Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25220733 | 0.91 | JAK2 (0.43) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL23209287 | 0.88 | JAK2 (0.42) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423996 | 0.87 | JAK2 (0.40) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423997 | 0.86 | JAK2 (0.43) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423873 | 0.86 | JAK2 (0.46) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL30063091 | 0.85 | JAK2 (0.41) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423967 | 0.82 | JAK2 (0.38) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL25271092 | 0.82 | JAK2 (0.40) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423972 | 0.82 | JAK2 (0.38) | JAK2JAK1TYK2JAK3MAP3K5 | |
| SCHEMBL31423958 | 0.82 | JAK2 (0.38) | JAK2JAK1TYK2JAK3MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| CN-119930611-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119930610-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025054386-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-115298177-B | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20230183250-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-15 | — | — | US | disclosed |
| US-20230183250-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-06-15 | — | — | US | disclosed |
| US-20230002376-A1 | BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-20230002376-A1 | BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| CN-115298177-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-4041731-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072232-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183250-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | JAK2 232/4885JAK1 605/4885TYK2 304/4885 |
| US-20230002376-A1 | BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | JAK2 181/4885JAK1 331/4885TYK2 310/4885 |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | JAK2 2076/4885JAK1 1378/4885TYK2 2563/4885 |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | JAK2 1817/4885JAK1 866/4885TYK2 2925/4885 |
| US-20210107901-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CDK1, CCNI | JAK2 311/4885JAK1 932/4885TYK2 372/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | JAK2 311/4885JAK1 932/4885TYK2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.